Lin Chih-Yang, Wang Shih-Wei, Chen Yen-Ling, Chou Wen-Yi, Lin Ting-Yi, Chen Wei-Cheng, Yang Chen-Yu, Liu Shih-Chia, Hsieh Chia-Chu, Fong Yi-Chin, Wang Po-Chuan, Tang Chih-Hsin
Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.
Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.
Cell Death Dis. 2017 Aug 3;8(8):e2964. doi: 10.1038/cddis.2017.354.
Chondrosarcoma is the second most common primary malignancy of bone, and one of the most difficult bone tumors to diagnose and treat. It is well known that increased levels of vascular endothelial growth factor-C (VEGF-C) promote active tumor lymphangiogenesis and lymphatic tumor spread to regional lymph nodes. Brain-derived neurotrophic factor (BDNF) is known to promote metastasis in human chondrosarcoma cells. Knowing more about the mechanism of BDNF in VEGF-C expression and lymphangiogenesis in human chondrosarcoma would improve our understanding as how to prevent chondrosarcoma angiogenesis and metastasis, which currently lacks effective adjuvant treatment. Here, we found that BDNF expression was at least 2.5-fold higher in the highly migratory JJ012(S10) cell line as compared with the primordial cell line (JJ012). In addition, VEGF-C expression and secretion was markedly increased in JJ012(S10) cells. Conditioned medium from JJ012(S10) cells significantly promoted migration and tube formation of human lymphatic endothelial cells (LECs), whereas knockdown of BDNF attenuated LEC migration and tube formation by suppressing VEGF-C production in JJ012(S10) cells. Mechanistic investigations indicated that BDNF facilitated VEGF-C-dependent lymphangiogenesis through the MEK/ERK/mTOR signaling pathway. We also showed that microRNA (miR)-624-3p expression was negatively regulated by BDNF via the MEK/ERK/mTOR cascade. Importantly, BDNF knockdown profoundly inhibited tumor-associated lymphangiogenesis in vivo. Further analyses identified that BDNF promoted tumor lymphangiogenesis by downregulating miR-624-3p in human chondrosarcoma tissues. In conclusion, this study is the first to reveal the mechanism underlying BDNF-induced lymphangiogenesis. We suggest that BDNF may serve as a promising therapeutic target for the restriction of VEGF-C-mediated tumor lymphangiogenesis and lymphatic metastasis.
软骨肉瘤是第二常见的原发性骨恶性肿瘤,也是最难诊断和治疗的骨肿瘤之一。众所周知,血管内皮生长因子C(VEGF-C)水平升高会促进肿瘤活跃的淋巴管生成以及肿瘤经淋巴管扩散至区域淋巴结。脑源性神经营养因子(BDNF)已知可促进人软骨肉瘤细胞的转移。进一步了解BDNF在人软骨肉瘤中VEGF-C表达及淋巴管生成的机制,将有助于我们理解如何预防目前缺乏有效辅助治疗手段的软骨肉瘤血管生成和转移。在此,我们发现与原始细胞系(JJ012)相比,高迁移性的JJ012(S10)细胞系中BDNF表达至少高2.5倍。此外,JJ012(S10)细胞中VEGF-C的表达和分泌显著增加。JJ012(S10)细胞的条件培养基显著促进人淋巴管内皮细胞(LEC)的迁移和管腔形成,而敲低BDNF可通过抑制JJ012(S10)细胞中VEGF-C的产生来减弱LEC的迁移和管腔形成。机制研究表明,BDNF通过MEK/ERK/mTOR信号通路促进VEGF-C依赖性淋巴管生成。我们还发现,微小RNA(miR)-624-3p的表达受BDNF通过MEK/ERK/mTOR级联反应的负调控。重要的是,敲低BDNF可在体内显著抑制肿瘤相关的淋巴管生成。进一步分析发现,BDNF通过下调人软骨肉瘤组织中的miR-624-3p来促进肿瘤淋巴管生成。总之,本研究首次揭示了BDNF诱导淋巴管生成的潜在机制。我们认为,BDNF可能是限制VEGF-C介导的肿瘤淋巴管生成和淋巴转移的一个有前景的治疗靶点。